Savolitinib-osimertinib significantly prolonged progression-free survival compared to chemotherapy in EGFR mutation-positive, MET-amplified Chinese NSCLC patients. The combination was well tolerated, and showed improved objective response rates over standard chemotherapy, offering a potential oral treatment option for patients failing previous EGFR TKI therapy.
Study
|
Multicentre, open-label, phase 3 randomised controlled trial [SACHI] |
| Advanced, EGFR mutation-positive, MET-amplified NSCLC after 1st line EGFR TKI therapy failure |
| Savolitinib-osimertinib (n=106) vs chemotherapy (n=105)
|
Efficacy
|
ORR: 58% vs 34% |
| mPFS (3rd gen EGFR TKI-naive): 9.8 mos vs 5.4 mos (HR 0.34 [0.21-0.56]) |
| mPFS (ITT): 8.2 mos vs 4.5 mos (HR 0.34 [0.23-0.49])
|
Safety
|
Grade >=3 AE: neutrophil count decreased (14% vs 26%), anaemia (4% vs 23%) |
| Drug-related deaths: 2% vs Not reported
|
Lancet. Published online January 13, 2026.
http://doi.org/10.1016/S0140-6736(25)01811-2
Reviewed by Ulas D. Bayraktar, MD on Jan 21, 2026
